BeyondSpring (BYSI) Non-Current Assets (2015 - 2026)
BeyondSpring (BYSI) posted Non-Current Assets of $4.9 million for Q1 2026, down 2.95% sequentially from $5.1 million in Q4 2025, and down 12.12% YoY from $5.6 million in Q1 2025.
BeyondSpring (BYSI) Non-Current Assets (2015 - 2026) Analysis & Trends
BeyondSpring has reported Non-Current Assets for 12 years, with the latest figure at $4.9 million in Q1 2026.
- Quarterly Non-Current Assets fell 12.12% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 12.12% YoY) and the FY2025 annual result came in at $5.1 million, down 11.97% from the prior year.
- Non-Current Assets fell to $4.9 million in Q1 2026 per BYSI's latest filing, from $5.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $8.0 million in Q2 2022 and troughed at $4.9 million in Q1 2026.
- A 5-year average of $6.1 million and a median of $5.7 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets jumped 198.51% in 2022, then fell 17.02% in 2023.
- Over 5 years, Non-Current Assets stood at $7.7 million in 2022, then slipped by 17.02% to $6.4 million in 2023, then declined by 10.19% to $5.7 million in 2024, then retreated by 11.97% to $5.1 million in 2025, then declined by 2.95% to $4.9 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $4.9 million, $5.1 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | BeyondSpring | 30.64 Mn | 30.64 Mn | - | 4.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.71 Mn |
| Mar 31, 2026 | 4.90 Mn |
| Dec 31, 2025 | 5.05 Mn |
| Sep 30, 2025 | 5.07 Mn |
| Jun 30, 2025 | 5.33 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 5.74 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Dec 31, 2023 | 6.39 Mn |
| Jun 30, 2023 | 7.09 Mn |
| Dec 31, 2022 | 7.70 Mn |
| Jun 30, 2022 | 8.04 Mn |
| Dec 31, 2021 | 6.53 Mn |
| Sep 30, 2021 | 3.70 Mn |
| Jun 30, 2021 | 2.69 Mn |
| Mar 31, 2021 | 2.72 Mn |
| Dec 31, 2020 | 3.64 Mn |
| Sep 30, 2020 | 3.71 Mn |
| Jun 30, 2020 | 3.75 Mn |
| Mar 31, 2020 | 3.75 Mn |